Skip to main content

Table 2 Lipids, CRP concentration and WOMAC score changes in patients treated with placebo and L-carnitine before and after 12 weeks of treatment

From: The effect of L-Carnitine supplementation on clinical symptoms, C-reactive protein and malondialdehyde in obese women with knee osteoarthritis: a double blind randomized controlled trial

  

L-carnitine group (n = 34)

Pb

Placebo group (n = 36)

Pc

Pd

LDL cholesterol (mg/dL)

before

136.13 ± 43.71

0.240

126.92 ± 35.33

0.380

0.316

after

130.97 ± 29.46

 

122.94 ± 44.18

 

0.372

change

−7.68 ± 37.07

 

−3.05 ± 20.59

 

0.525

HDL cholesterol (mg/dL)

before

64.97 ± 26.35

0.434

64.08 ± 19.60

0.413

0.867

after

62.26 ± 11.35

 

67.94 ± 15.24

 

0.083

change

−3.85 ± 8.35

 

2.5 ± 18.12

 

0.265

Triglycerides (mg/dL)

before

185.53 ± 92.50

0.23

193.63 ± 80.05

0.888

0.684

after

169.15 ± 73.81

 

193.44 ± 78.60

 

0.188

change

−20.50 ± 97.72

 

1.50 ± 63.18

 

0.265

Total cholesterol (mg/dL)

before

226.74 ± 50.55

0.021

220.71 ± 42.70

0.259

0576

after

212.24 ± 41.39

 

210.89 ± 61.00

 

0.914

change

−18.47 ± 44.33

 

−8.94 ± 46.77

 

0.385

CRP (mg/dL)

before

3.40 ± 2.51b

0.142

3.9 ± 3.92 a

0.682

0.618

after

3.00 ± 3.05

 

4.40 ± 5.90

 

0.969

change

−0.6 ± 2.52

 

0.09 ± 3.72

 

0.383

MDA (mg/dL)

Before

33.3 ± 36.09

0.03

24.2 ± 14.7

0.36

0.36

After

26.1 ± 22.22

 

21.03 ± 11.4

 

0.76

change

−5.22 ± 24.98

 

−2.08 ± 13.5

 

0.22

Pain index

before

7.34 ± 3.4

0.001

8.63 ± 3.63

0.001

0.322

after

4.71 ± 2.65

 

5.89 ± 3.54

 

0.119

change

−2.91 ± 2.03

 

−2.89 ± 2.21

 

0.964

Stiffness

before

2.28 ± 1.72

0.001

3.02 ± 2.18

0.001

0.107

after

1.56 ± 1.50

 

2.00 ± 1.74

 

0.261

change

−1 ± 1.00

 

−1.11 ± 1.43

 

0.223

Physical function

before

17.82 ± 7.75

0.001

20.63 ± 8.77

0.001

0.142

after

11.15 ± 6.56

 

15.61 ± 8.17

 

0.014

change

−6.97 ± 3.95

 

−5.11 ± 5.29

 

0.102

Global Score

before

27.45 ± 11.44

0.001

32.29 ± 12.93

0.001

0.088

after

17.41 ± 9.81

 

23.50 ± 12.02

 

0.024

change

−10.59 ± 5.58

 

−9.11 ± 6.44

 

0.342

  1. Mean ± SD (all such values)
  2. aMedian; IQR (all such values for non-normally distributed variables)
  3. bDetermined with the use of paired Student’s t tests for differences between baseline and follow-up in the L-carnitine group
  4. cDetermined with the use of paired Student’s t tests for differences between baseline and follow-up in the placebo group
  5. dDetermined with the use of independent samples t tests between L-carnitine and placebo groups
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us